Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate X842 takes a new approach to provide improved management of esophagitis and GERD symptoms. 

Today's GERD medication has significant shortcomings

De-risked development program – phase II study in planning

X842 provides improved acid control

18.5 million

people in initial, niche target population


individuals exposed to the active metabolite of X842 in clinical trials

Team with experience from development of Losec and Nexium

Cinclus Pharma AB

Mäster Samuelsgatan 60

(C/O Regus)

111 21 Stockholm



Christer Ahlberg, CEO

+46 706 753 330

Kjell Andersson, CSO

+46 733 337 906

Peter Unge, CMO

+46 705 763 780

Copyright © All Rights Reserved